Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-11
2007-12-11
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S079000
Reexamination Certificate
active
11759704
ABSTRACT:
Compounds identified by the general formula (I) are used for the treatment of Alzheimer's disease
REFERENCES:
patent: 2811531 (1957-10-01), Holly et al.
patent: 2820799 (1958-01-01), Wagner
patent: 2844585 (1958-07-01), Cavallito
patent: 3019227 (1962-01-01), Erner
patent: 3238224 (1966-03-01), Ohara et al.
patent: 3326917 (1967-06-01), Freimiller et al.
patent: 3406199 (1968-10-01), Helmut et al.
patent: 3686180 (1972-08-01), Sutton
patent: 3936457 (1976-02-01), Schwender et al.
patent: 4739064 (1988-04-01), Shaw
patent: 5380920 (1995-01-01), Paust et al.
patent: 5489694 (1996-02-01), Paust et al.
patent: 5559113 (1996-09-01), Schwartz et al.
patent: 5670657 (1997-09-01), Kojima et al.
patent: 5750560 (1998-05-01), Christen et al.
patent: 5925668 (1999-07-01), Biewenga et al.
patent: 6090842 (2000-07-01), Packer et al.
patent: 6111109 (2000-08-01), Denny et al.
patent: 6204288 (2001-03-01), Pershadsingh et al.
patent: 6235772 (2001-05-01), Packer et al.
patent: 6387945 (2002-05-01), Packer et al.
patent: 6489336 (2002-12-01), Miyamoto et al.
patent: 6495690 (2002-12-01), Kulkarni et al.
patent: 6605637 (2003-08-01), Harnett et al.
patent: 6706722 (2004-03-01), Emig et al.
patent: 6844449 (2005-01-01), Laban et al.
patent: 7030251 (2006-04-01), Laban et al.
patent: 7109362 (2006-09-01), Klatt et al.
patent: 0 527 687 (1993-02-01), None
patent: 0 869 126 (2002-07-01), None
patent: 1 500 650 (2005-01-01), None
patent: 1 571 146 (2005-09-01), None
patent: 08-193026 (1996-07-01), None
patent: 2 039 733 (1995-07-01), None
patent: WO 93/14070 (1993-07-01), None
patent: WO 93/20040 (1993-10-01), None
patent: WO 99/29693 (1999-06-01), None
patent: WO 00/50391 (2000-08-01), None
patent: WO 00/53601 (2000-09-01), None
patent: WO 00/59899 (2000-10-01), None
patent: WO 00/76505 (2000-12-01), None
patent: WO 01/25226 (2001-04-01), None
patent: WO 02/076177 (2002-10-01), None
patent: WO 03/053366 (2003-07-01), None
patent: WO 03/087035 (2003-10-01), None
patent: WO 2005/048933 (2005-06-01), None
patent: WO 2005/048945 (2005-06-01), None
patent: WO 2005/123079 (2005-12-01), None
patent: WO 2006/029115 (2006-03-01), None
Akkas, “Molecular Investigation Of Antioxidants On Rat Brain Tissues,”Thesis Submitted to the Graduate School of Natural and Applied Sciences of The Middle East Technical University(2003).
Bartolini et al., “β-Amyloid Aggregation Induced By Human Acetylcholinesterase: Inhibition Studies,”Biochem. Pharmacol., 65:407-416 (2003).
Carlier et al., “Potent, Easily Synthesized Huperzine A-Tacrine Hybrid Acetycholoinesterase Inhibitors,”Bioorg. Med. Chem. Lett., 9:2335 (1999).
Cavallito et al., “Amino-and Ammonium-Alkylaminobenzoquinones As Curarimimetic Agents,”J. Amer. Chem. Society, 72:2661-2665 (1950).
Cavallito, “Quaternary Ammonium Alkylaminobenzoquinoes,”Chem. Abstr., 53:294-295 (1959).
Cutler et al., “Review Of The Next Generation Of Alzheimer's Disease Therapeutics: Challenges For Drug Development,”Prog. Neuro-Psychopharmacol,&Biol. Psychiat., 25:27-57 (2001).
Gardent, “On Some Dihydro-and Tetrahydroisoquinolines Substituted In The 1 Position With Cyclane Or Cyclene Groups,”Annales Pharmaceutiques Francaises, 18:381-393 (1960) [(In Italian) “De Quelques Dihydro-et tetrahydro-isoquinoléines substituées en 1 par des groupes cycylaniques ou cycléniques”].
Gurkan et al., “Syntheses of Novel Indole Lipoic Acid Derivatives And Their Antioxidant Effects On Lipid Peroxidation,”Arch. Pharm. Chem. Life Sci., 338:67-73 (2005).
Harnett et al., “Novel Lipoic Acid Analogues That Inhibit Nitric Oxides Synthase,”Bioorganic&Med. Chem. Ltrs., 12:1439-1442 (2002).
Luo et al., “Ruthenium Tetraamine Chemistry Of Self-Assembled Monolayers On Gold Surfaces: Substitution And Reactivity At The Monolayer Interface,”Langmuir, 14:3602-3606, (1998).
Melchiorre et al., “Acetylcholinesterase Noncovalent Inhibitors Based On A Polyamine Backbone For Potential Use Against Alzheimer's Disease,”J. Med. Chem., 41:4186-4189 (1998).
Merck Index, 1137-1138, pp. 185-186, Cavallito 53:294-295 1959.
Pang et al., “Highly Potent, And Low Cost Bis-Tetrahydroaminacrine Inhibitors Of Acetylcholinesterase,”J. Biol. Chem., 271:23646-23649 (1996).
Rosini et al., “Prazosin-Related Compounds, Effect Of Transforming The Piperazinylquinazoline Moiety Into An Aminomethyltetrahydroacridine System On The Affinity For α1-Adrenoreceptors,”J. Med. Chem.46:4895-4903 (2003).
Rosini et al., “Rational Approach To Discover Multipotent Anti-Alzheimer Drugs,”J. Med. Chem., 48:360-363 (Published on Internet Web Dec. 31, 2004).
Rosini et al. “Discovery of Multipotent Drugs For The Treatment Of Alzheimer's Disease,”Key Lecture:KL10(Jun. 2005).
Schweizer et al., “Sulfonyliminoimidazolidines. A new class of Oral Hypoglycemic Agents,”J. Med. Chem., American Chemical Society, 26:964-970 (1983).
Shepard, “Papaverine Analogs. IV. 1-Cycloaliphatic-6,7-Dimethoxy-Isoquinolines,”J. Organic Chem., 19:415-418 (1954).
Stark et al., “New potent Histamine H3-Receptor Antagonists Of The Amide Type,”Eur. J. Pharma. Sci., Elsevier Amsterdam, NL, 3:95-104 (1995).
Stark et al., “Search For Novel Leads for Histamine H-3-Receptor Antagonists: Amine Derivates,”Pharmazie, 52(6):419-423 (1997).
Steinberg et al., “A Hydrophobic Binding Site In Acetylcholinesterase,”J. Med. Chem., 18:1056-1061 (1975).
Webb, “Affinity Of Benzoquinonium And Ambenonium Derivatives For The Acetylcholine Receptor, Tested On The Electroplax, And For Acetylcholinesterase In Solution,”Biochim. Biophys. Acta, 102:172-184 (1965).
Wurst, Slide Presentation (May 2005).
Andrisano Vincenza
Bartolini Manuela
Melchiorre Carlo
Rosini Michela
Alma Mater Studiorum-Universita'di Bologna
Desai Rita
Marshall & Gerstein & Borun LLP
LandOfFree
Tetrahydro-acridine and dithiolane derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydro-acridine and dithiolane derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydro-acridine and dithiolane derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3850401